Our institute is having trouble completing these long runs. They seem to die towards the end of both reads, camera goes out of focus, etc. They are being run on an upgraded HS2000. FYI, the samples all passed on MiSeq 2x300. We are looking for slightly more yield meta, amp.Has anyone had similar issues, any success, any advice?
-
-
I guess it depends on how good of success you're after. We had a 2x250 v2 rapid run finish this morning and the results were relatively good. There was decreased quality toward the end of each read, but this was due primarily to two tiles (I think they were the exact same ones for each of the reads), so it turned out that the vast majority of reads were quite good. I should note that there was a bigger issue with the end of read 2, where a large block of tiles had problems. The latter issue combined with the same tiles showing some quality problems in both read 1 and 2 would be compatible with a camera problem, since there was an obvious per-tile difference...thereby suggesting that the problem isn't due to the chemistry itself.
I can't give any advice, as I don't personally deal with the sequencer, but that's at least the sort of thing that we're getting at the moment. -
With an n=1 we had no problems. Got about 250M reads per lane.Comment
-
Are you guys using a native 2500 V4 capable instrument, or an older upgraded 2000?Comment
-
Our run was on an upgraded older 2000.Comment
-
Comment
-
-
I hope the problem has been solved by now!
Anyway: With 2 native HS2500 we regularly get >300M cpf per flowcell and between 80 and 85% Q30 for amplicon data.Comment
-
We've given up for the time being in favor of V1 rapids. Our instrument is an older one that we bought in 2011 and then upgraded to 2500. We're thinking that the camera/optics aren't capable of running 500 cycles?Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment